Market Cap (In GBp)
2.42 Million
Revenue (In GBp)
46 Thousand
Net Income (In GBp)
-5.41 Million
Avg. Volume
25.42 Thousand
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8.0-75.0
- PE
- -
- EPS
- -
- Beta Value
- -0.155
- ISIN
- USU5500L1045
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Dr. Paul Pagano Ph.D.
- Employee Count
- -
- Website
- https://www.lunglifeai.com
- Ipo Date
- 2021-07-08
- Details
- LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.
More Stocks
-
1616A Metaverse Company
1616
-
OKMNOKMIN RESOURCES INC
OKMN
-
RZREFRazor Energy Corp.
RZREF
-
ARCXF
-
GYST
-
600017Rizhao Port Co., Ltd.
600017
-
POOJAENT
-
KRRAILK&R RAIL ENGINEERING LIMITED
KRRAIL